Home » Specialists » Dr Ben Yap Beng Khiong
MBChB (Dundee)
MRCP (UK)
FRCP (Lond)
FRCR (Lond),
CST(Clinical Oncology, UK)
Location
LANGUAGES SPOKEN:
CLINICAL INTERESTS:
8.00 am – 12.00 noon(AM) | 1.00 pm – 5.00pm(PM) | |
---|---|---|
Monday | ||
Tuesday | – | |
Wednesday | Available | Available |
Thursday | ||
Friday | Available | – |
Saturday |
Dr Yap Beng Khiong is a highly regarded oncologist known for his expertise in the diagnosis, treatment, and management of a wide range of cancers. With extensive training and experience in medical oncology, Dr Yap specializes in the treatment of various malignancies, including breast cancer, colorectal cancer, head and neck cancer, lung cancer, skin cancer, thyroid cancer, and urologic cancers.
Dr Yap is particularly recognized for his comprehensive approach to cancer care, integrating cutting-edge medical treatments with personalized care plans for each patient. He is dedicated to providing
individualized treatment strategies that focus on improving outcomes and quality of life for cancer patients.
Dr. Yap Beng Khiong is not only an expert in oncology but also a distinguished scholar who has been recognized with several prestigious awards throughout his career for his contributions to cancer research and clinical excellence. His expertise spans a wide array of cancers, including breast, colorectal, head and neck, lung, skin, thyroid, and urologic cancers.
Awards
• Craniospinal Radiotherapy in a man with Severe Kyphoscoliosis. B K Yap, B Magee, E Vollans. Clin Onc (2001) 13: 117-119,
• Are serial bone scans useful for the follow-up of clinically localized, low to intermediate grade, prostate cancer managed with a watchful observation protocol? B K Yap, R Choo, G DeBoer, L Klotz, C Danjoux, G Morton. BJU International, 2003 May; 91 (7): 613-7.
• Barium paste: Useful in primary tumour localisation in oral cancer. B K Yap and N J Slevin. Br J Radiol. 2004 Feb; 77(914):143-5.
• Cribriform-morular variant of papillary thyroid carcinoma: molecular characterization of a case with neuroendocrine differentiation and aggressive behavior. Cameselle-Teijeiro J, Menasce LP, Yap BK, Colaco RJ, Castro P, Celestino R, Ruíz-Ponte C, Soares P, Sobrinho-Simões M. Am J Clin Pathol. 2009 Jan; 131(1):134-42.
• Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation. Azrif M, Slevin NJ, Sykes AJ, Swindell R, Yap BK. Radiother Oncol. 2008 Oct;89(1):105-13. 2008 Jun 23.
• IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult. Ho KF, Fowler JF, Sykes AJ, Yap BK, Lee LW, Slevin NJ. Acta Oncol. 2009;48(3):431-9.
• A clinical case report of cribriform-morular variant of papillary thyroid carcinoma with neuroendocrine differentiation and aggressive behaviour in a patient with familial adenomatous polyposis coli. R.J. Colaco, L.P. Menasce, M. Ranson, M. Sobrinho Simoes, J. Cameselle Teijeiro, S. Vinjamuri, and B. K. Yap. Thyroid Science 4(3):CR1-3, 2009
• Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Slevin, N. Clin Oncol 2010; 22(3): 185-191.
• Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. Mallick U, Harmer C, Yap BK, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A. N Engl J Med. 2012 May 3;366(18):1674-85.
• Monitoring dosimetric impact of weight loss with kilovoltage (kV) cone beam CT (CBCT) during parotid-sparing IMRT and concurrent chemotherapy. Ho KF, Marchant T, Moore C, Webster G, Rowbottom C, Penington H, Lee L, Yap BK, Sykes A, Slevin N. Int J Radiat Oncol Biol Phys. 2012 Mar 1; 82(3):e375-82.
• A double-blind, placebo-controlled, randomised trial of active manuka honey and standard oral care for radiation-induced oral mucositis. Bardy J, Molassiotis A, Ryder WD, Mais K, Sykes A, Yap BK, Lee L, Kaczmarski E, Slevin N. Br J Oral Maxillofac Surg. 2012 Apr; 50(3):221-6.
• Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap BK, Strasburger CJ, Wu Z. J Clin Endocrinol Metab. 2011 Jun;96(6):1864-72
• Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, Miles EA, Miah AB, Newbold K, Tanay M, Adab F, Jefferies SJ, Scrase C, Yap BK, A’Hern RP, Sydenham MA, Emson M, Hall E; PARSPORT trial management group. Lancet Oncol. 2011 Feb;12(2):127-36
• Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. Mitra I, Nichani JR, Yap BK, Homer JJ. J Laryngol Otol. 2011 May; 125(5):497-501.
• Can synchronous chemotherapy be added to accelerated hypofractionated radiotherapy in patients with base of tongue cancer? Jegannathen A, Swindell R, Yap BK, Lee L, Sykes A, Mais K, Sanghera P, Hartley A, Glaholm J, Slevin N. Clin Oncol (R Coll Radiol). 2010 Apr;22(3):185-91
• Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Colaco RJ, Betts G, Donne A, Swindell R, Yap BK, Sykes AJ, Slevin NJ, Homer JJ, Lee LW. Clin Oncol (R Coll Radiol). 2013 Mar(3):171-7.
• Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, Homer J, Sykes AJ, Lee LW, Yap BK, Slevin NJ. Head Neck. 2013 Dec 17. doi: 10.1002/hed.23577.
• Use of pre-ablation radioiodine-131 scan to assess the impact of surgical volume and specialization following thyroidectomy for differentiated thyroid carcinoma. Yap B K, Homer J, Parrott N, Loughran S, Murby B, Swindell R, Gandhi A. Eur Thyroid J 2013;2:275-281
• Anaplastic Thyroid Cancer: The Addition of Systemic Chemotherapy to radiotherapy led to an observed improvement in survival—A Single Centre Experience and the Review of the Literature. Natalie M. Lowe, Sean Loughran, Nicholas J. Slevin, and Beng K. Yap. The Scientific World Journal; vol. 2014:1–8, 2014.
• Carotid dosimetry for T1 glottic cancer radiotherapy. Garcez K, Lim CC, Whitehurst P, Thomson D, Ho KF, Lowe M, Sykes A, Lee L, Yap B, Slevin N. Br J Radiol. 2014 Feb 17:20130754
• Postoperative Management of Thyroid Cancer. Tips and Tricks in Endocrine Surgery. Beng K Yap; 2014, pp 205-212. ISBN: 978-0-85729-982-6 (Print) 978-1-4471-2146-6 (Online)
• No adverse affect in clinical outcome using low pre-ablation diagnostic 131I activity in differentiated thyroid cancer: refuting thyroid stunning effect. Yap Beng K & Murby B. J Clin Endo Metab, 2014 Feb
• Thyroid incidentalomas discovered on positron emission tomography CT scanning – Malignancy rate and significance of standardised uptake values. Brindle R, Mullan D, Yap BK, Gandhi A. Eur J Surg Oncol: 2014.
• Management Of The Compromised Airway And The Role Of Tracheostomy In Anaplastic Thyroid Carcinoma. Navin Mani, Katherine McNamara, Natalie Lowe, Sean Loughran, Beng K Yap. Head & Neck; 2014
• Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk. David Thomson, Chris Boylan, Tom Liptrot, Adam Aitkenhead, Lip Lee, Beng Yap, Andrew Sykes, Carl Rowbottom, Nicholas Slevin. Radiation Oncology 2014
• Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. David J Thomson, Kean F Ho, Linda Ashcroft, Kim Denton, Guy Betts, Kathleen L Mais, Kate Garcez, Beng K Yap, Lip W Lee, Andrew J Sykes, Carl G Rowbottom, Nicholas J Slevin. Acta Oncologica 2015: 54(1): 88=98
• Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. A Gandhi, B Ranganathan, SA Thiryayi, M Rowland, Beng K Yap. Eur J Surg Oncol 2015
• Surgical management of medullary thyroid cancer: which guidelines should we follow? Alex Bowen, Navin Mani, Susannah Penney, Sean Loughran, Beng Yap. J Laryng Otolog 2015.
• Cisplatin plus Capecitabine as First-Line Chemotherapy for Recurrent or Metastatic Head and
Neck Squamous Cell Cancer: Experience Outside of a Trial Setting. Andrew J McPartlin, K Mais, C Barker, Ric Swindell, K Mitchell, A Sykes, L Lee, B Yap, Nicholas J Slevin. Chemotherapy 2013;59(1): 1-7.
• Roles of Ki67 in Breast cancer-Important for management? CH Yip; N Bhoo-Pathy; JM Daniel; YC Foo; AK Mohamed; MM Abdullah; YS Ng; BK Yap; R Pathmanathan: Volume 17, Issue 3, March 2016, Page 1077-1082
• The role of neoadjuvant chemotherapy in the surgical management of women with breast
cancer in a middle-income country.Cheng-Har Yip, Mastura Yusof, Matin Mellor Abdullah, YokeChing Foo, Beng-Khiong Yap, Yi Siang Ng, Rajadurai Pathmanathan: Advances in Modern Oncology research: doi: 10.18282/amor.v3.is1.197
• Retrospective Analysis of Cancer Care Performance and Survival Outcome for Nasopharyngeal Carcinoma at a leading Cancer Treatment Centre in Malaysia 2008-2012. Matin Mellor Abdullah, Yoke Ching Foo, Beng Khiong Yap, Catherine May Ling Lee, L P Hoo, Teck Onn Lim. Asian Pac J Cancer Prev, 20 (6), 1701-1708; June 2019
• Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐ dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy. Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng: Asia-Pacific Journal of Clinical Oncology 18(9); Nov 2021
Site Map | PDPA | Terms of Use | Disclaimer |
Contact Us | Career | Media Contact